NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

骨髓增生性疾病治療藥的全球市場(2020年∼2027年)

Global Myeloproliferative Disorders Drugs Market - 2020-2027

出版商 DataM Intelligence 商品編碼 1004991
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
骨髓增生性疾病治療藥的全球市場(2020年∼2027年) Global Myeloproliferative Disorders Drugs Market - 2020-2027
出版日期: 2021年05月12日內容資訊: 英文 180 Pages
簡介

全球骨髓增生性疾病治療藥市場成長,骨髓增生性疾病的罹患率增加,強力的開發平台藥物的存在,生活方式的變化,高齡人口增加等成為主要原因。但,治療和藥物的高成本,有妨礙該市場成長的可能性。

本報告提供全球骨髓增生性疾病治療藥市場的相關調查,市場機會和影響,成長及阻礙因素,各藥物類型、流通管道、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 全球骨髓增生性疾病治療藥市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球骨髓增生性疾病治療藥市場- 市場定義和概要

第3章 全球骨髓增生性疾病治療藥市場-摘要整理

  • 各藥物類型的市場明細
  • 各流通管道的市場明細
  • 各地區的市場明細

第4章 全球骨髓增生性疾病治療藥市場-市場動態

  • 影響市場的要素
    • 成長要素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球骨髓增生性疾病治療藥市場- 產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球骨髓增生性疾病治療藥市場-COVID-19分析

  • 市場上的Covid-19分析
    • COVID-19前的市場方案
    • 目前市場方案
    • COVID-19後或今後方案
  • Covid-19的價格趨勢
  • 需求與供給的頻譜
  • 大流行時的市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 全球骨髓增生性疾病治療藥市場- 各藥物類型

  • 簡介
  • 各藥物類型的市場規模分析,及與前一年同期比較成長分析
  • 各藥物類型的市場魅力指數
    • 抗腫瘤劑
    • 脫甲基化劑
    • Imatinib mesylate
    • 其他

第8章 全球骨髓增生性疾病治療藥市場- 各流通管道

  • 簡介
  • 流通管道各市場區隔的市場規模分析,及與前一年同期比較成長分析
  • 流通管道各市場區隔的市場魅力指數
    • 醫院藥局
    • 零售藥局
    • 藥妝店
    • 其他

第9章 全球骨髓增生性疾病治療藥市場- 各地區

  • 簡介
  • 各地區的市場規模分析,及與前一年同期比較成長分析
  • 各地區市場魅力指數
  • 北美
    • 簡介
    • 主要地區具體動態
    • 藥的各種類的市場規模分析,及與前一年同期比較成長分析(%)
    • 各流通管道的市場規模分析,及與前一年同期比較成長分析(%)
    • 各國市場規模分析,及與前一年同期比較成長分析(%)
  • 歐洲
    • 簡介
    • 主要每個地區的動態
    • 各藥物類型:市場規模分析,及與前一年同期比較成長分析
    • 各流通管道:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 南美
    • 簡介
    • 主要每個地區的動態
    • 各藥物類型:市場規模分析,及與前一年同期比較成長分析
    • 各流通管道:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 亞太地區
    • 簡介
    • 主要每個地區的動態
    • 各藥物類型:市場規模分析,及與前一年同期比較成長分析
    • 各流通管道:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 中東和非洲
    • 簡介
    • 主要每個地區的動態
    • 各藥物類型:市場規模分析,及與前一年同期比較成長分析
    • 各流通管道:市場規模分析,及與前一年同期比較成長分析

第10章 全球骨髓增生性疾病治療藥市場-競爭情形

  • 競爭模式
  • 市場定位/佔有率分析
  • 合併和收購分析

第11章 全球骨髓增生性疾病治療藥市場-企業簡介

  • Novartis AG
    • 企業概要
    • 產品系列、概要
    • 要點
    • 財務概要
  • Incyte Corporation,
  • Epizyme, Inc.,
  • Bristol-Myers Squibb Company,
  • Pfizer Inc,
  • Takeda Pharmaceuticals Company Limited,
  • Apotex Inc,
  • Teva Pharmaceutical Industries Ltd,
  • F. Hoffmann-La Roche Ltd,
  • Eli Lilly and Company.

第12章 全球骨髓增生性疾病治療藥市場- 重要考察

第13章 全球骨髓增生性疾病治療藥市場-DataM

  • 附錄
  • 關於本公司、服務
  • 諮詢方式

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Market Overview

The Global Myeloproliferative Disorders Drugs Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Myeloproliferative disorders are the disease of blood and bone marrow that have an unknown cause, and there is a wide range of symptoms. Myeloproliferative disorders are generally considered a clonal disorder that begins with one or more changes in the DNA of a single stem cell in the bone marrow. The changes to the hematopoietic stem cell cause the cell to reproduce repeatedly, creating more abnormal stem cells. These will become one or more types of blood cells. These get worst with time as the number of extra blood cells builds up in the bone marrow and bloodstream. Signs of these disorders include fatigue, itchy skin, night sweats, bone pain, fever, weight loss and major complications include Excessive bleeding, which can happen with a minor cut, bruising, or when capillaries break under the skin are blood clots (thrombosis); the disease changing into leukemia. The treatment depends on which myeloproliferative disorder you have. Some of the most common treatments are chemotherapy, surgery, radiation therapy, phlebotomy, stem cell therapy and others.

Market Dynamics

The global Myeloproliferative Disorders Drugs market growth is driven by the growing incidence of myeloproliferative disorders, Presence of strong pipeline drugs and changing lifestyle, increasing geriatric population are the major factors of the market.

Growing incidence of myeloproliferative disorders, is expected to drive the growth in the forecast period

The most common form of the myeloproliferative disease is chronic myelogenous leukemia (CML). According to the National Cancer Institute, CML is diagnosed in more than 8,000 patients per year in the United States. The incidence of polycythemia vera in the United States is 5 per 1 million per year, and Essential thrombocythemia has an incidence of 1.5 per 100,000. In contrast, myelofibrosis incidence is estimated to be around 0.9 per 100,000 per year. These increase in the number of myeloproliferative disorders cases will add to the overall global myeloproliferative disorders drugs market.

Presence of strong pipeline drugs, is expected to drive the growth in the forecast period

AbbVie conducting a Phase 1 clinical trial to Evaluate the Safety and Tolerability and Pharmacokinetics of Navitoclax Monotherapy in Combination with Ruxolitinib and Celecoxib in treating Myeloproliferative disorder patients is expected to complete by 2023, which will increase the demand for the Myeloproliferative disorder drugs market in the forecast period.

Celgene Corporation: A Phase 3, Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions is expected to complete by 2025, which will increase the demand for the Myeloproliferative disorder drugs market in the forecast period.

High Cost of Treatment and Drugs is likely to hamper the global myeloproliferative disease drugs market.

According to the study presented in the American Society of Hematology, annual medical and drug costs for patients with myelofibrosis neoplasms were 2 to 6 times that of patients with ailments other than cancer. For patients with myelofibrosis, the mean total annual costs were $34,690, with outpatient costs accounting for 53% of the total (mean, $18,395). Inpatient visits (23%, $8106), drug costs (22%, $7803), and emergency department visits (1%, $386) accounted for the remaining costs. Patients with myelofibrosis incurred the greatest costs, followed by patients with essential thrombocythemia (mean annual total, $19,672) and polycythemia vera (mean annual total, $11,927).

COVID-19 Impact Analysis

Due to the covid-19 pandemic outbreak, the market for Global myeloproliferative disorders drugs market was seen to be down, due to the barriers in production and sales segments. Since the outbreak led to the shutdown of all manufacturing firms except for masks, sanitizers and ventilators. Hence, the Drugs were manufactured less compared to previous years, during the outbreak.

Segment Analysis

Based on the Drug Type, the global Myeloproliferative Disorders drugs market is segmented into JAK1/JAK2 inhibitor, Anti-Neoplastics, Demethylation Agents, Imatinib mesylate and Others

JAK1/JAK2 inhibitor & Imatinib mesylate segments accounts the largest share in the market.

Imatinib mesylate (Gleevec), protein-tyrosine kinase inhibitor (TKI), manufactured by Novartis Pharmaceuticals Corp, is FDA approved drug in 2001 for use in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in the chronic phase. It binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This agent inhibits TK encoded by the bcr-abl oncogene and receptor TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Inhibition of the bcr-abl TK results in decreased proliferation and enhanced apoptosis in malignant cells of Philadelphia-positive (Ph+) hematological malignancies such as CML.

Ruxolitinib is a type of targeted cancer drug called a cancer growth blocker. A cancer growth blocker blocks the growth factors that trigger the cancer cells to divide and grow. Ruxolitinib works by blocking a gene that is important in the production of blood cells. This gene is called JAK2. In December 2014, the US Food and Drug Administration (FDA) expanded the approval of the JAK1/JAK2 inhibitor, ruxolitinib (Jakafi), for the treatment of Polycythemia vera in patients. In November 2011, the JAK1/JAK2 inhibitor, ruxolitinib (Jakafi), manufactured by Incyte Corporation, became the first US Food and Drug Administration (FDA)-approved drug for intermediate- or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.

Based on Distribution channel, the hospital pharmacies are expected to dominate the Global Myeloproliferative Disorders Drugs market during the forecast period

The hospital pharmacies held the largest share in the global Myeloproliferative Disorders drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.Also the medications can be administrated by intravenously under supervision of medical practioners at these locations.

Geographical Analysis

North America region holds the largest market share global Myeloproliferative Disorders Drugs market

North America holds the largest market in the global Myeloproliferative Disorders Drugs market due to the high incidence of cancer, according to the American cancer society, there are about 800 new cases of neuroblastoma each year in the United States. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and immunotherapy methods, the total availability of advanced technological tools, FDA approval of orphan drugs for the treatment of neuroblastoma and also the presence of a vast number of organizations engaged in R&D activities related to cancer vaccines.

The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Chia Tai Tianqing Pharmaceutical Group Co., Ltd Conducting Phase I Study of TQ05105 Tablets in Subjects with Myeloproliferative Neoplasms.

Competitive Landscape

The Global Myeloproliferative Disorders Drugs Market is quite competitive with some key competitors like Novartis AG, Eli Lilly and Company, Incyte Corporation, Epizyme, Inc., Bristol-Myers Squibb Company, Pfizer Inc, Takeda Pharmaceuticals Company Limited, Apotex Inc, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors. For instance, M.D. Anderson Cancer Center in Collaboration with Incyte Corporation Evaluating the Ruxolitinib and Lenalidomide Combination as a Therapy for Patients with Myelofibrosis is under Phase 2 clinical trials.

Novartis AG

Company Overview: Novartis AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world. It is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA). It has 110,000 (2020) total employees and generates $48.66 billion (2020) revenue.

Product Portfolio: The company portfolio includes Oncology, Cardiovascular, Renal and Metabolic Medicine, Immunology, Dermatology, Ophthalmology, Neuroscience, Respiratory and Others.

Key developments:

Novartis - ABL001 (asciminib), a BCR-ABL inhibitor, is under Phase 3 clinical trials in Chronic myeloid leukemia (CML) patients.

Why Purchase the Report?

  • Visualize the composition of the Myeloproliferative Disorders drugs segmentation by drug type, distribution channel, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in Myeloproliferative Disorders drugs by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of Myeloproliferative Disorders drugs - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global Myeloproliferative Disorders drugs report would provide an access to an approx. 53 market data table, 45 figures and 240 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Myeloproliferative Disorders Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Myeloproliferative Disorders Drugs Market - Market Definition and Overview

3. Global Myeloproliferative Disorders Drugs Market - Executive Summary

  • 3.1. Market Snippet by Drug Type
  • 3.2. Market Snippet by Distribution Channel
  • 3.3. Market Snippet by Region

4. Global Myeloproliferative Disorders Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. Growing incidence of myeloproliferative disorders
      • 4.1.1.2. Presence of strong pipeline drugs
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of treatment and drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Myeloproliferative Disorders Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Myeloproliferative Disorders Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Myeloproliferative Disorders Drugs Market - By Drug Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
  • 7.3. Market Attractiveness Index, By Drug Type Segment
      • 7.3.1.1. JAK1/JAK2 inhibitor*
      • 7.3.1.2. Introduction
      • 7.3.1.3. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Anti-Neoplastics
    • 7.3.3. Demethylation Agents
    • 7.3.4. Imatinib mesylate
    • 7.3.5. Others

8. Global Myeloproliferative Disorders Drugs Market - By Distribution Channel

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 8.3. Market Attractiveness Index, By Distribution Channel Segment
    • 8.3.1. Hospital Pharmacies *
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Drug stores
    • 8.3.4. Others

9. Global Myeloproliferative Disorders Drugs Market - By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. U.S.
      • 9.4.5.2. Canada
      • 9.4.5.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.5.
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. Germany
      • 9.5.6.2. U.K.
      • 9.5.6.3. France
      • 9.5.6.4. Italy
      • 9.5.6.5. Spain
      • 9.5.6.6. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.5.1. Brazil
      • 9.6.5.2. Argentina
      • 9.6.5.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.5.1. China
      • 9.7.5.2. India
      • 9.7.5.3. Japan
      • 9.7.5.4. Australia
      • 9.7.5.5. Rest of Asia Pacific
  • 9.8. Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Global Myeloproliferative Disorders Drugs Market - Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Global Myeloproliferative Disorders Drugs Market - Company Profiles

  • 11.1. Novartis AG*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Incyte Corporation,
  • 11.3. Epizyme, Inc.,
  • 11.4. Bristol-Myers Squibb Company,
  • 11.5. Pfizer Inc,
  • 11.6. Takeda Pharmaceuticals Company Limited,
  • 11.7. Apotex Inc,
  • 11.8. Teva Pharmaceutical Industries Ltd,
  • 11.9. F. Hoffmann-La Roche Ltd,
  • 11.10. Eli Lilly and Company.

LIST NOT EXHAUSTIVE

12. Global Myeloproliferative Disorders Drugs Market - Premium Insights

13. Global Myeloproliferative Disorders Drugs Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us